26 May 2013
Keywords: gilead, reports, 48-wk, data, hiv, study, sciences
Article | 14 February 2005
Gilead Sciences of the USA has reported 48-week data from study 934 indicating that a regimen of Truvada, which is comprised ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
14 February 2005
24 May 2013
© 2013 thepharmaletter.com